Autolus Therapeutics (AUTL)
(Delayed Data from NSDQ)
$4.08 USD
-0.13 (-3.09%)
Updated Apr 25, 2024 04:00 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AUTL 4.08 -0.13(-3.09%)
Will AUTL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AUTL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AUTL
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
Strength Seen in Autolus Therapeutics PLC Sponsored ADR (AUTL): Can Its 6.3% Jump Turn into More Strength?
AUTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
2seventy bio, Inc. (TSVT) Surges 28.2%: Is This an Indication of Further Gains?
Autolus (AUTL) Selects Cardinal Health for Cell Therapy Supply
Has Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year?
Other News for AUTL
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
AUTL Makes Notable Cross Below Critical Moving Average
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors